Endocytic downregulation of ErbB receptors: Mechanisms and relevance in cancer

Histochemistry and Cell Biology

Volumn 129, Issue 5, 2008, Pages 563-578

  Roepstorff, Kirstine ^a   Grøvdal, Lene ^a   Grandal, Michael ^a   Lerdrup, Mads ^a   Van Deurs, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endocytosis; Endosomal sorting; Epidermal growth factor receptor; ErbB2; Lysosomal degradation; Ubiquitin

Indexed keywords

CETUXIMAB; CLATHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; TANESPIMYCIN; TRASTUZUMAB; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; ENDOCYTOSIS; GROWTH REGULATION; HEAD AND NECK CANCER; HUMAN; INTERNALIZATION; LIGAND BINDING; LYSOSOME; MONOTHERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DOWN-REGULATION; ENDOCYTOSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 42449114402     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-008-0401-3     Document Type: Review

References (167)

1. Alwan HA, van Zoelen EJ, van Leeuwen JE (2003) Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 278:35781-35790
2. Antonyak MA, Moscatello DK, Wong AJ (1998) Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273:2817-2822
3. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268-5282
4. Bache KG, Slagsvold T, Stenmark H (2004) Defective downregulation of receptor tyrosine kinases in cancer. EMBO J 23:2707-2712
5. Bache KG, Stuffers S, Malerød L, Slagsvold T, Raiborg C, Lechardeur D, Walchli S, Lukacs GL, Brech A, Stenmark H (2006) The ESCRT-III subunit hVps24 is required for degradation but not silencing of the epidermal growth factor receptor. Mol Biol Cell 17:2513-2523
6. Bakowska JC, Jupille H, Fatheddin P, Puertollano R, Blackstone C (2007) Troyer syndrome protein spartin is mono-ubiquitinated and functions in EGF receptor trafficking. Mol Biol Cell 18:1683-1692
7. Barriere H, Nemes C, Du K, Lukacs GL (2007) Plasticity of polyubiquitin recognition as lysosomal targeting signals by the endosomal sorting machinery. Mol Biol Cell 18:3952-3965
8. Batra S, Castelino-Prabhu S, Wikstrand C, Zhu X, Humphrey P, Friedman H, Bigner D (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6:1251-1259
9. Baulida J, Carpenter G (1997) Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp Cell Res 232:167-172
10. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271:5251-5257
11. Benmerah A, Lamaze C, Begue B, Schmid SL, Dautry-Varsat A, Cerf-Bensussan N (1998) AP-2/Eps15 interaction is required for receptor-mediated endocytosis. J Cell Biol 140:1055-1062
12. Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ (2005) The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 102:15024-15029
13. Breuleux M (2007) Role of heregulin in human cancer. Cell Mol Life Sci 64:2358-2377
14. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552
15. Cao Z, Wu X, Yen L, Sweeney C, Carraway III KL (2007) Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 27:2180-2188
16. Carpenter G, Cohen S (1979) Epidermal growth factor. Annu Rev Biochem 48:193-216
17. Chan R, Hardy WR, Dankort D, Laing MA, Muller WJ (2004) Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development 131:5551-5560
18. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD (1997) Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324(Pt 3):855-861
19. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
20. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y (2002) Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 21:2407-2417
21. Citri A, Skaria KB, Yarden Y (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284:54-65
22. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y (2004) Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 5:1165-1170
23. Confalonieri S, Salcini AE, Puri C, Tacchetti C, Di Fiore PP (2000) Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J Cell Biol 150:905-912
24. Crosetto N, Tikkanen R, Dikic I (2005) Oncogenic breakdowns in endocytic adaptor proteins. FEBS Lett 579:3231-3238
25. Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ (1997) Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 17:5410-5425
26. Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S (2006) EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene 25:6497-6509
27. Decker SJ (1990) Epidermal growth factor and transforming growth factor-alpha induce differential processing of the epidermal growth factor receptor. Biochem Biophys Res Commun 166:615-621
28. Dikic I (2003) Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans 31:1178-1181
29. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H (2003) Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278:28950-28960
30. Ebner R, Derynck R (1991) Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 2:599-612
31. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinsdottir T, Brice A, van Bergen En Henegouwen PM, Fon EA (2006) A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8:834-842
32. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507-517
33. Fischer JA, Eun SH, Doolan BT (2006) Endocytosis, endosome trafficking, and the regulation of Drosophila development. Annu Rev Cell Dev Biol 22:181-206
34. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387
35. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102:1915-1920
36. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220
37. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763-773
38. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495-505
39. Ge H, Gong X, Tang CK (2002) Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98:357-361
40. Giebel B, Wodarz A (2006) Tumor suppressors: control of signaling by endocytosis. Curr Biol 16:R91-R92
41. Goetz MP, Toft DO, Ames MM, Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176
42. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS (2007) EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28:1408-1417
43. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655
44. Grøvdal LM, Stang E, Sorkin A, Madshus IH (2004) Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300:388-395
45. Gruenberg J, Stenmark H (2004) The biogenesis of multivesicular endosomes. Nat Rev Mol Cell Biol 5:317-323
46. Haglund K, Rusten TE, Stenmark H (2007) Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. Crit Rev Oncog 13:39-74
47. Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006) Hypophosphorylation of Residue Y1045 Leads to Defective Downregulation of EGFRvIII. Cancer Biol Ther 5:1361-1368
48. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057-4065
49. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284:2-13
50. Haslekas C, Breen K, Pedersen KW, Johannessen LE, Stang E, Madshus IH (2005) The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell 16:5832-5842
51. Hawryluk MJ, Keyel PA, Mishra SK, Watkins SC, Heuser JE, Traub LM (2006) Epsin 1 is a polyubiquitin-selective clathrin-associated sorting protein. Traffic 7:262-281
52. Hayashi T, Sakamoto S (1988) Radioimmunoassay of human epidermal growth factor-hEGF levels in human body fluids. J Pharmacobiodyn 11:146-151
53. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D (2003a) Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 278:23343-23351
54. Hendriks BS, Wiley HS, Lauffenburger D (2003b) HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 85:2732-2745
55. Hicke L (1999) Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol 9:107-112
56. Hicke L, Riezman H (1996) Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell 84:277-287
57. Hirano S, Kawasaki M, Ura H, Kato R, Raiborg C, Stenmark H, Wakatsuki S (2006) Double-sided ubiquitin binding of Hrs-UIM in endosomal protein sorting. Nat Struct Mol Biol 13:272-277
58. Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557-1567
59. Hommelgaard AM, Roepstorff K, Vilhardt F, Torgersen ML, Sandvig K, van Deurs B (2005) Caveolae: stable membrane domains with a potential for internalization. Traffic 6:720-724
60. Hong RL, Spohn WH, Hung MC (1999) Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5:1884-1891
61. Huang F, Sorkin A (2005) Growth factor receptor binding protein 2-mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell 16:1268-1281
62. Huang F, Kirkpatrick D, Jiang X, Gygi S, Sorkin A (2006) Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 21:737-748
63. Huang F, Goh LK, Sorkin A (2007) EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci USA 104:16904-16909
64. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
65. Hurwitz E, Stancovski I, Sela M, Yarden Y (1995) Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 92:3353-3357
66. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
67. Jaramillo ML, Leon Z, Grothe S, Paul-Roc B, Abulrob A, O'Connor McCourt M (2006) Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312:2778-2790
68. Jiang X, Sorkin A (2003) Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 4:529-543
69. Jiang X, Huang F, Marusyk A, Sorkin A (2003) Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14:858-870
70. Jones RB, Gordus A, Krall JA, MacBeath G (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439:168-174
71. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
72. Kani K, Park E, Landgraf R (2005) The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry 44:15842-15857
73. Kazazic M, Roepstorff K, Johannessen LE, Pedersen NM, van Deurs B, Stang E, Madshus IH (2006) EGF-induced activation of the EGF receptor does not trigger mobilization of caveolae. Traffic 7:1518-1527
74. Kirkham M, Fujita A, Chadda R, Nixon SJ, Kurzchalia TV, Sharma DK, Pagano RE, Hancock JF, Mayor S, Parton RG (2005) Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J Cell Biol 168:465-476
75. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M (1997) A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-2109
76. Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388
77. Kolling R, Hollenberg CP (1994) The ABC-transporter Ste6 accumulates in the plasma membrane in a ubiquitinated form in endocytosis mutants. EMBO J 13:3261-3271
78. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr relat cancer 8:83-96
79. Lamaze C, Schmid SL (1995) Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase. J Cell Biol 129:47-54
80. Le Borgne R (2006) Regulation of Notch signalling by endocytosis and endosomal sorting. Curr Opin Cell Biol 18:213-222
81. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385-3397
82. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 119:85-95
83. Lerdrup M, Bruun S, Grandal MV, Roepstorff K, Kristensen MM, Hommelgaard AM, van Deurs B (2007) Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell 18:3656-3666
84. Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y (1996) Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12:1117-1125
85. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y (1998) c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12:3663-3674
86. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029-1040
87. Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y (2000) c-Cbl is a suppressor of the neu oncogene. J Biol Chem 275:35532-35539
88. Linggi B, Carpenter G (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16:649-656
89. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH (2002) Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156:843-854
90. Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH (2005) Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116:359-367
91. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58:903-913
92. Menard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22:6570-6578
93. Miaczynska M, Pelkmans L, Zerial M (2004) Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 16:400-406
94. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-22801
95. Montgomery RB, Moscatello DK, Wong AJ, Cooper JA, Stahl WL (1995) Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J Biol Chem 270:30562-30566
96. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539
97. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ (1996) Transformational and altered signal transduction by a naturally occurring mutantEGF receptor. Oncogene 13:85-96
98. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ (1998) Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor. J Biol Chem 273:200-206
99. Mullin JM (2004) Epithelial barriers, compartmentation, and cancer. Sci STKE 2004:pe2-
100. Muthuswamy SK, Gilman M, Brugge JS (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19:6845-6857
101. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086
102. Neckers L (2002) Heat shock protein 90 is a rational molecular target in breast cancer. Breast Dis 15:53-60
103. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15:419-424
104. Nesterov A, Wiley HS, Gill GN (1995) Ligand-induced endocytosis of epidermal growth factor receptors that are defective in binding adaptor proteins. Proc Natl Acad Sci USA 92:8719-8723
105. Nishikawa R, Ji X, Harmon R, Lazar C, Gill G, Cavenee W, Huang H (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. PNAS 91:7727-7731
106. Normanno N, Bianco C, De Luca A, Salomon DS (2001) The role of EGF-related peptides in tumor growth. Front Biosci 6:D685-D707
107. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS (2005) The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6:243-257
108. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787
109. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ (2003) Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 94:50-56
110. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82:186-194
111. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167
112. Omerovic J, Santangelo L, Puggioni EM, Marrocco J, Dall'Armi C, Palumbo C, Belleudi F, Di ML, Frati L, Torrisi MR, Cesareni G, Gulino A, Alimandi M (2007) The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 21:2849-2862
113. Orlichenko L, Huang B, Krueger E, McNiven MA (2006) Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J Biol Chem 281:4570-4579
114. Orth JD, Krueger EW, Weller SG, McNiven MA (2006) A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res 66:3603-3610
115. Park JM, Yang X, Park JJ, Press OW, Press MF (1999) Assessment of novel anti-p185HER-2 monoclonal antibodies for internalization-dependent therapies. Hybridoma 18:487-495
116. Pedersen MW, Pedersen N, Damstrup L, Villingshoj M, Sonder SU, Rieneck K, Bovin LF, Spang-Thomsen M, Poulsen HS (2005a) Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J Cell Biochem 96:412-427
117. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS (2005b) Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 93:915-923
118. Pelkmans L, Kartenbeck J, Helenius A (2001) Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3:473-483
119. Pelkmans L, Puntener D, Helenius A (2002) Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296:535-539
120. Peschard P, Park M (2003) Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3:519-523
121. Polo S, Di Fiore PP (2006) Endocytosis conducts the cell signaling orchestra. Cell 124:897-900
122. Polo S, Sigismund S, Faretta M, Guidi M, Capua MR, Bossi G, Chen H, De Camilli P, Di Fiore PP (2002) A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416:451-455
123. Polo S, Pece S, Di Fiore PP (2004) Endocytosis and cancer. Curr Opin Cell Biol 16:156-161
124. Qiu XB, Goldberg AL (2002) Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci USA 99:14843-14848
125. Raiborg C, Stenmark H (2002) Hrs and endocytic sorting of ubiquitinated membrane proteins. Cell Struct Funct 27:403-408
126. Raiborg C, Bache KG, Mehlum A, Stang E, Stenmark H (2001) Hrs recruits clathrin to early endosomes. EMBO J 20:5008-5021
127. Raiborg C, Malerød L, Pedersen NM, Stenmark H (2007) Differential functions of Hrs and ESCRT proteins in endocytic membrane trafficking. Exp Cell Res (in press)
128. Reutens AT, Begley CG (2002) Endophilin-1: a multifunctional protein. Int J Biochem Cell Biol 34:1173-1177
129. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP (2008) ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19:73-80
130. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12(Suppl 1):S3-S8
131. Sachse M, Urbe S, Oorschot V, Strous GJ, Klumperman J (2002) Bilayered clathrin coats on endosomal vacuoles are involved in protein sorting toward lysosomes. Mol Biol Cell 13:1313-1328
132. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
133. Sandvig K, Torgersen ML, Raa HA, van Deurs B (2008) Clathrin-independent endocytosis: from nonexisting to an extreme degree of complexity. Histochem Cell Biol (in press)
134. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68:589-596
135. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S (2005) Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102:2760-2765
136. Solit DB, Chiosis G (2008) Development and application of Hsp90 inhibitors. Drug Discov Today 13:38-43
137. Sorkin A, Carpenter G (1993) Interaction of activated EGF receptors with coated pit adaptins. Science 261:612-615
138. Sorkin A, von Zastrow M (2002) Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3:600-614
139. Sorkin A, McKinsey T, Shih W, Kirchhausen T, Carpenter G (1995) Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. J Biol Chem 270:619-625
140. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I (2002) Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416:183-187
141. Stang E, Blystad FD, Kazazic M, Bertelsen V, Brodahl T, Raiborg C, Stenmark H, Madshus IH (2004) Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol Biol Cell 15:3591-3604
142. Stern KA, Place TL, Lill NL (2007) EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J (in press)
143. Sugawa N, Ekstrand A, James C, Collins V (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606
144. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825-3829
145. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60:3081-3087
146. Thomsen P, Roepstorff K, Stahlhut M, van Deurs B (2002) Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 13:238-250
147. Tikhomirov O, Carpenter G (2000) Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 275:26625-26631
148. Tikhomirov O, Carpenter G (2001) Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin. J Biol Chem 276:33675-33680
149. Tikhomirov O, Carpenter G (2003) Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63:39-43
150. Torrisi MR, Lotti LV, Belleudi F, Gradini R, Salcini AE, Confalonieri S, Pelicci PG, Di Fiore PP (1999) Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization. Mol Biol Cell 10:417-434
151. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287
152. Vastag B (2006) HSP-90 inhibitors promise to complement cancer therapies. Nat Biotechnol 24:1307
153. Wang Z, Zhang L, Yeung TK, Chen X (1999) Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 10:1621-1636
154. Warren CM, Landgraf R (2006) Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal 18:923-933
155. Waterman H, Sabanai I, Geiger B, Yarden Y (1998) Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 273:13819-13827
156. Waterman H, Alroy I, Strano S, Seger R, Yarden Y (1999) The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 18:3348-3358
157. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y (2002) A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21:303-313
158. Way TD, Kao MC, Lin JK (2004) Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 279:4479-4489
159. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772
160. Williams RL, Urbe S (2007) The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol 8:355-368
161. Worthylake R, Opresko LK, Wiley HS (1999) ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274:8865-8874
162. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708
163. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99:12847-12852
164. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1-13
165. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19:2013-2023
166. Zheng FF, Kuduk SD, Chiosis G, Munster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N (2000) Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res 60:2090-2094
167. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V, Band H (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278:13829-13837